{"organizations": [], "uuid": "abbc450f2557594445c10a6430ef2e9c2a708bd7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-innate-pharma-and-medimmune-enter/brief-innate-pharma-and-medimmune-enter-clinical-trial-collaboration-idUSFWN1PP05X", "country": "US", "domain_rank": 408, "title": "BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-30T14:18:00.000+02:00", "replies_count": 0, "uuid": "abbc450f2557594445c10a6430ef2e9c2a708bd7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-innate-pharma-and-medimmune-enter/brief-innate-pharma-and-medimmune-enter-clinical-trial-collaboration-idUSFWN1PP05X", "ord_in_thread": 0, "title": "BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-innate pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "medimmune", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - INNATE PHARMA SA:\n* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION\n* COLAB TO EVALUATE COMBINATION OF IPH5401 ANTIBODY AND IMFINZI(Â®) (DURVALUMAB) IN A PHASE I/II STUDY FOR PATIENTS WITH SELECTED SOLID TUMORS\n* INNATE WILL SPONSOR STUDY WITH COSTS EQUALLY SHARED BY BOTH PARTIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T14:18:00.000+02:00", "crawled": "2018-01-31T16:52:04.032+02:00", "highlightTitle": ""}